Mark Jeffrey DeLong - 23 Oct 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
23 Oct 2023
Net transactions value
-$6,031
Form type
4
Filing time
24 Oct 2023, 16:18:36 UTC
Previous filing
22 Feb 2023
Next filing
17 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $6,031 -131 -0.25% $46.04 51,622 23 Oct 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on a Restricted Stock Unit release.
F2 This includes 412 shares from 04/30/2023 ESPP purchase.